logo
Share SHARE
FONT-SIZE Plus   Neg

EXACT Sciences Says It Submitted Final Module Of PMA For Cologuard To The FDA

EXACT Sciences Corp. (EXAS), a molecular diagnostics company focused on the early detection and prevention of colorectal cancer, Monday said that it submitted the final module of the premarket approval or PMA for Cologuard, the company's stool DNA or sDNA colorectal cancer screening test, to the U.S. Food and Drug Administration or FDA. The final module which was submitted on June 7, comprised of data from the company's DeeP-C clinical trial. The trial analyzed data from about 10,000 patients at 90 sites between the ages of 50 and 84 who were at average risk for colorectal cancer.

EXACT Sciences also announced that the role of COO Maneesh Arora would now also include the oversight of U.S. sales and marketing. The company is also in the search for a senior financial officer.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the annual letter to shareholders of hedge fund Pershing Square Capital Management L.P, CEO Bill Ackman admitted that the investment in Valeant Pharmaceuticals was a huge mistake. Valeant stock was down 19.2 percent in 2016 and tarnished the image of the hedge fund. A video posted by an outraged mother of her 13-year-old special needs son getting a thorough pat-down by a Transportation Security Administration officer at Dallas/Fort Worth International Airport has gone viral. The Texas woman, Jennifer Williamson, posted the two-minute video to Facebook on Sunday, showing her son who suffers from sensory processing disorder or SPD getting a thorough pat-down. The average age of a Fortune 500 company CEO is 58 years, but a number of big names are shouldering this responsibility well into their golden years. Some of these CEOs have become synonymous with the companies they have helped transform into global giants, and their performance is reflected in the...
comments powered by Disqus
Follow RTT